In contrast, among adenocarcinoma patients, significant differences were observed in median OS, with a median OS of 18.0 months for those treated with ipilimumab plus nivolumab without TP53 mutation, 39.0 months for those treated with pembrolizumab without TP53 mutation, 15.0 months for those treated with ipilimumab plus nivolumab with TP53 mutation, and 32.0 months for those treated with pembrolizumab with TP53 mutation (p < 0.001), (Figure 10B). Here, TP53 is linked to adenocarcinoma.